HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Skip to content
The CRC Digest
▸ TREATMENT
HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer — ESMO Gastrointestinal Oncology
An exploratory analysis from the CAPRI-2 GOIM trial examined HER2 gene alterations in patients with RAS/BRAF wild-type, microsatellite stable metastatic colorectal cancer treated with FOLFIRI chemotherapy plus